Add onc brain to your Home Screen: tap Share, then Add to Home Screen.
BART: adjuvant pelvic RT post-cystectomy cuts 2yr locoregional failure (LRFFS 87.1% vs 76.0%, HR 0.43, p=0.04); no OS benefit (HR 0.78, ns).
Bladder carried the day. BART, the first phase III of adjuvant pelvic RT after radical cystectomy, roughly halves locoregional failure (8% vs 26%) in high-risk MIBC, benefit concentrating in N+/T3+ pts. OS unchanged, and the trial predates adjuvant nivolumab, so the RT+IO question stays open.
read the full digest →Studies · 88
- BART2yr locoregional FFS 87.1% vs 76.0% with adjuvant RT post-cystectomy, HR 0.43 (0.20-0.96), p=0.04; OS not improved (HR 0.78, ns).
- ENZARAD (ANZUP 1303)Primary MFS endpoint negative (HR 0.88, p=0.34); enzalutamide benefit concentrated in cN1 (HR 0.43) and planned-pelvic-RT (HR 0.47) subgroups.
- ARS Appropriate Use Criteria: Locoregionally Recurrent Rectal CancerMargin-negative (R0) resection drives survival and local control; preop RT or systemic therapy downsizes tumor to improve R0 likelihood.
- PRIMARY2PSMA-PET avoided biopsy in 49% while csPCa detection (12% vs 16%, diff −3.7%, 95% CI −8.9 to 1.5) was non-inferior to systematic biopsy.
- INDIBLADE2yr bladder-intact EFS 78% (67-90), OS 96% (91-100) with induction ipi/nivo then chemoRT in cT2-4aN0-2 MIBC.
- DOREMY5-yr LRFS 97.4% with dose-reduced 36 Gy/18fx preop RT in myxoid liposarcoma, median f/u 66mo.
- REVELUTIONAdjusted total plaque volume +68.9mm³ with leuprolide vs relugolix at 12mo, GnRH agonist accelerating coronary atherosclerosis.
- KEYNOTE-689 vs NIVOPOSTOP3y DFS ~63% vs 53% adding adjuvant nivo to post-op chemoRT (NIVOPOSTOP); perioperative pembro hits EFS (KEYNOTE-689) in resectable LA-HNSCC.
- GEC-ESTRO APBI Patient Selection Guidelines (2026 Update)Updated selection expands low-risk APBI to age >40, ≤30mm, pN0/pN1mi, all histologies, DCIS at ≥2mm margins; BRCA/TNBC/age<40/EIC/extensive-LVI contraindicated.
- ORIOLESABR cut 6-mo progression to 19% vs 61% (P=.005) and improved mPFS (NR vs 5.8mo, HR 0.30) in oligomet HSPC.
- ARTOPSA response 92% vs 68.3% (OR 5.34) and PFS HR 0.35 adding SBRT to abiraterone in oligomet CRPC.
- WOLVERINEMDT+SOC cut PFS events vs SOC alone (HR 0.44, p<0.0001) across 6 oligomet prostate RCTs; OS HR 0.63 (p=0.051) not significant.